Exelixis
American biotechnology company
EXEL Nasdaq
SEC CIK 939767 LEI 254900PJQB59O2O95R37
Follow Exelixis
Weekly email: filings, results
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $2.3B | $782.6M |
| FY25 | $2.2B | $521.3M |
| FY24 | $1.8B | $207.8M |
| FY23 | $1.6B | $182.3M |
| FY22 | $1.4B | $231.1M |
| FY21 | $987.5M | $111.8M |
| FY20 | $967.8M | $321M |
| FY19 | $853.8M | $690.1M |
| FY18 | $452.5M | $154.2M |
| FY17 | $191.5M | −$70.2M |
| FY16 | $37.2M | −$161.7M |
| FY15 | $25.1M | −$261.3M |
| FY14 | $31.3M | −$238.2M |
| FY13 | $47.5M | −$145.3M |
| FY12 | $289.6M | $75.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY26 | 96.4% | 37.6% | 33.7% |
| FY25 | 96.5% | 27.9% | 24% |
| FY24 | 96% | 9.3% | 11.4% |
| FY23 | 96.4% | 12.5% | 11.3% |
| FY22 | 96.3% | 20% | 16.1% |
| FY21 | 96.3% | 11.1% | 11.3% |
| FY20 | 96.6% | 38.2% | 33.2% |
| FY19 | 96.9% | 51.4% | 80.8% |
| FY18 | 96.7% | 36.7% | 34.1% |
| FY17 | 96.6% | −14.7% | −36.7% |
| FY16 | 89.5% | −326.6% | −435.1% |
| FY15 | 91.9% | −893.9% | −1040.6% |
| FY14 | 96.4% | −640.5% | −760.1% |
| FY13 | 100% | −258% | −306.3% |
| FY12 | 100% | 30.9% | 26.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | $875.8M |
| FY25 | $671.5M |
| FY24 | $292.9M |
| FY23 | $334.9M |
| FY22 | $346.6M |
| FY21 | $178.6M |
| FY20 | $514.1M |
| FY19 | $382.4M |
| FY18 | $144.5M |
| FY17 | $208.7M |
| FY16 | −$141.5M |
| FY15 | −$235.9M |
| FY14 | −$200.9M |
| FY13 | −$125.9M |
| FY12 | −$160.2M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY26 | $947.5M |
| FY25 | $652M |
| FY24 | $550.4M |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
- Exelixis
- Healthcare median
Show the numbers
| Year | Exelixis | Healthcare median |
|---|---|---|
| FY26 | 33.7% | −11.1% |
| FY25 | 24% | −30.6% |
| FY24 | 11.4% | −47% |
| FY23 | 11.3% | −58% |
| FY22 | 16.1% | −80.4% |
| FY21 | 11.3% | −71.9% |
| FY20 | 33.2% | −62.2% |
| FY19 | 80.8% | −46.3% |
| FY18 | 34.1% | −49.6% |
| FY17 | −36.7% | −45.9% |
| FY16 | −435.1% | −36% |
| FY15 | −1040.6% | −38.4% |
| FY14 | −760.1% | −35.5% |
| FY13 | −306.3% | −37.1% |
| FY12 | 26.1% | −29.1% |